Comparative Pharmacology
Head-to-head clinical analysis: CAPREOMYCIN SULFATE versus SODIUM P A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPREOMYCIN SULFATE versus SODIUM P A S.
CAPREOMYCIN SULFATE vs SODIUM P.A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting translation initiation. Also alters membrane permeability.
Sodium P.A.S. (para-aminosalicylate) inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid, thereby suppressing bacterial growth.
15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.
4 g orally three times daily (total 12 g/day). For intravenous administration, 4 g (10 mL of 40% solution) diluted in 250 mL of 5% dextrose or normal saline infused over 2-3 hours three times daily.
None Documented
None Documented
Terminal elimination half-life: 24-40 hours (prolonged in renal impairment; anuria may extend to 96-120 hours).
0.5–1 hour (normal renal function); prolonged to ≥10 hours in renal impairment (requires dose adjustment).
Primarily renal (80-90% as unchanged drug via glomerular filtration). Biliary/fecal elimination: <1%.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal ≤10%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent